Tezosentan in Patients With Pulmonary Arterial Hypertension
Status:
Terminated
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
Multicenter, double-blind, randomized, placebo-controlled, cross-over study to demonstrate
that a single infusion of tezosentan has minimal effect on blood pressure in patients with
pulmonary arterial hypertension, treated with endothelin receptor antagonists,
phosphodiesterase-5 inhibitors or a combination of both.